These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28752672)

  • 1. Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study.
    Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Takada T; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Arai T; Sugimoto C; Hattori N; Watanabe K; Tamada T; Akazawa K; Tanaka T; Nakata K
    Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1182-1189. PubMed ID: 28752672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.
    Takada T; Mikami A; Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Akasaka K; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Sugimoto C; Arai T; Hattori N; Watanabe K; Tamada T; Yoshizawa H; Akazawa K; Tanaka T; Yagi K; Young LR; McCormack FX; Nakata K
    Ann Am Thorac Soc; 2016 Nov; 13(11):1912-1922. PubMed ID: 27513278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
    Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX;
    Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
    Wang Q; Luo M; Xiang B; Chen S; Ji Y
    Respir Res; 2020 Feb; 21(1):55. PubMed ID: 32059669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis.
    Argula RG; Kokosi M; Lo P; Kim HJ; Ravenel JG; Meyer C; Goldin J; Lee HS; Strange C; McCormack FX;
    Ann Am Thorac Soc; 2016 Mar; 13(3):342-9. PubMed ID: 26799509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
    Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
    Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
    Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
    Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis.
    Yoon HY; Hwang JJ; Kim DS; Song JW
    Orphanet J Rare Dis; 2018 Nov; 13(1):204. PubMed ID: 30428897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of Sirolimus for Lymphangioleiomyomatosis.
    Martirossian A; Shah S; Carrete L; Valle J; Valentine V
    Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summaries for patients. Sirolimus therapy in patients with lymphangioleiomyomatosis.
    Ann Intern Med; 2011 Jun; 154(12):I44. PubMed ID: 21690578
    [No Abstract]   [Full Text] [Related]  

  • 11. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
    Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
    Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience.
    Revilla-López E; Berastegui C; Méndez A; Sáez-Giménez B; Ruiz de Miguel V; López-Meseguer M; Monforte V; Bravo C; Pujana MA; Ramon MA; Gómez-Ollés S; Roman A;
    Sci Rep; 2021 May; 11(1):10171. PubMed ID: 33986388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
    Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
    Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
    El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Peters E; Haughey M; Bienfang D; Jones AM; Julien-Williams P; Cui Y; Villalba JA; Bagwe S; Maurer R; Rosas IO; Moss J; Henske EP
    Chest; 2017 Jun; 151(6):1302-1310. PubMed ID: 28192114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
    Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
    Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of mTOR inhibitors on the mortality and safety of patients with lymphangioleiomyomatosis on the lung transplantation waitlist: A retrospective cohort study.
    Sakurai T; Kanou T; Funaki S; Fukui E; Kimura T; Ose N; Inoue Y; Shintani Y
    Respir Investig; 2024 Jul; 62(4):657-662. PubMed ID: 38761480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
    Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
    Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
    Neurohr C; Hoffmann AL; Huppmann P; Herrera VA; Ihle F; Leuschner S; von Wulffen W; Meis T; Baezner C; Leuchte H; Baumgartner R; Zimmermann G; Behr J
    Respir Res; 2011 May; 12(1):66. PubMed ID: 21600034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.
    Glasgow CG; Pacheco-Rodriguez G; Steagall WK; Haughey ME; Julien-Williams PA; Stylianou MP; Gochuico BR; Moss J
    Chest; 2018 Feb; 153(2):339-348. PubMed ID: 28576630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphangioleiomyomatosis treatment with sirolimus.
    Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
    Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.